Research & Development

• Neurolutions was established out of Dr. Eric Leuthardt’s lab at Washington University in St. Louis.
• Initial funding support came from Ascension Health Ventures.
• Focused on technology development, clinical studies, and evidence generation.

Product Development & Regulatory Preparation

• Ascension Health Ventures engaged Incept, LLC to accelerate the transition from R&D to commercialization.
• Fred Khosravi joined the Board of Directors as Chairman.

Breakthrough Recognition

• The FDA granted IpsiHand “Breakthrough Medical Technology” status.
•  Recognized for providing more effective treatment options for debilitating conditions.

FDA De Novo Clearance

• Awarded FDA De Novo Market Authorization as the first Brain-Computer Interface product to receive clearance.
• Indicated for use in chronic stroke survivors.

Product Enhancement & Manufacturing Readiness

• Enhancements were made to improve user experience while addressing clinician and patient needs.
• Product was prepared for contract manufacturing.

Limited Market Launch

• Initial market release of IpsiHand.
• Strategic focus on:
  • Manufacturing
  • Lead generation
  • Sales
  • Screening
  • Fulfillment
  • Support

Full Market Launch

• IpsiHand officially launches to a broader market.
• Ongoing expansion and further development efforts.